UnitedHealth Group
UNH
$396.30
+1.77%
UnitedHealth Group is a diversified healthcare company operating through two primary platforms: UnitedHealthcare, which provides health insurance coverage to approximately 51 million members globally, and Optum, which offers healthcare services, pharmacy benefit management, and data analytics. As one of the largest private health insurers in the U.S., UnitedHealth holds a dominant market position, leveraging its integrated model to drive scale and efficiency across insurance and care delivery. The current investor narrative centers on the company's operational recovery from a challenging 2025, highlighted by a strong Q1 2026 earnings beat and better-than-expected Medicare reimbursement rates, which have fueled a significant stock rally. However, an unresolved Department of Justice investigation into Medicare billing practices and ongoing regulatory scrutiny over prior authorizations continue to cast a shadow, creating a debate between the company's fundamental strength and its legal and political overhangs.…
UNH
UnitedHealth Group
$396.30
Related headlines
Investment Opinion: Should I buy UNH Today?
We rate UNH as a Buy, driven by a strong Q1 2026 earnings recovery, a reasonable forward PE of 17.5x, and a consensus analyst target of $475.23, implying 20.9% upside. The company's dominant market position and stable revenue base provide a solid foundation for growth, and the recent operational improvements suggest a positive trajectory.
Sign up to view all
UNH 12-Month Price Forecast
The AI assessment leans bullish due to the strong Q1 earnings recovery and attractive forward valuation, but confidence is medium given the unresolved DOJ investigation and regulatory risks. The stock's 80% rally from its low suggests much of the good news is priced in, limiting upside. Key factors to watch include the resolution of the DOJ probe and the sustainability of earnings growth. If the investigation concludes favorably and earnings continue to beat, the stock could reach the high target; otherwise, it may face multiple compression. The stance would be upgraded to high confidence if the DOJ issue is resolved, and downgraded to neutral if earnings disappoint or regulatory pressure intensifies.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UnitedHealth Group's 12-month outlook, with a consensus price target around $475.23 and implied upside of +19.9% versus the current price.
Average Target
$475.23
0 analysts
Implied Upside
+19.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$313 - $529
Analyst target range
UnitedHealth is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.56 (where 1 is Strong Buy and 5 is Sell). The average target price is $475.23, implying an upside of approximately 20.9% from the current price of $392.95. The distribution shows a bullish tilt, with 10 recent ratings including 7 Buy/Overweight and 3 Hold, and no Sell ratings, indicating strong institutional confidence in the stock's recovery trajectory.
Drowning in data?
Find the real signal!
Bulls vs Bears: UNH Investment Factors
UnitedHealth presents a classic recovery story with strong fundamental tailwinds from its Q1 2026 earnings beat and reasonable forward valuation, but it is tempered by significant legal and regulatory risks. The bull case is supported by a 20.9% analyst upside and a forward PE of 17.5x, while the bear case hinges on the DOJ investigation and the stock's 80% rally from its low. Currently, the evidence slightly favors the bulls given the strong earnings recovery and analyst consensus, but the unresolved legal issues and political scrutiny create a high-risk, high-reward profile. The most critical tension is whether the operational recovery can sustain momentum and outweigh the potential financial and reputational damage from the DOJ probe, which could either validate the current valuation or trigger a sharp correction.
Bullish
- Strong Q1 2026 Earnings Beat: Q1 2026 EPS of $6.90 significantly exceeded the depressed Q4 2025 EPS of $0.011, demonstrating a robust operational recovery. Net income surged to $6.28 billion from just $10 million in the prior quarter, indicating a return to normal profitability.
- Forward PE Attractive at 17.5x: The forward PE of 17.51x is well below the trailing PE of 24.95x, implying the market expects substantial earnings growth. This valuation is reasonable for a company with a dominant market position and stable revenue, offering a potential value opportunity.
- Analyst Consensus Buy with 20.9% Upside: With a consensus rating of 'Buy' (mean 1.56) and an average target price of $475.23, analysts see a 20.9% upside from the current price of $392.95. The high target of $529 suggests even more optimism, reflecting confidence in the recovery.
- Revenue Stability and Scale: Q1 2026 revenue of $111.7 billion grew 1.96% YoY, maintaining a massive scale with 51 million members. The diversified model (UnitedHealthcare + Optum) provides resilience, as evidenced by stable revenue despite industry headwinds.
Bearish
- Unresolved DOJ Investigation: The ongoing Department of Justice investigation into Medicare billing practices poses legal and financial risk. Any adverse outcome could result in significant fines or changes to billing practices, potentially impacting future revenue and earnings.
- Regulatory and Political Overhang: Increased scrutiny over prior authorizations and government pressure on healthcare costs could limit pricing power and increase compliance costs. This is a persistent overhang that could cap valuation multiples.
- Recent Stock Rally May Limit Upside: The stock has rallied 80% off its 52-week low of $255.97, now trading at $392.95. This rapid appreciation has already priced in much of the recovery, reducing the margin of safety and increasing vulnerability to negative news.
- Weak Profitability Metrics: Despite the Q1 recovery, trailing net margin is only 2.69% and operating margin is 4.24%, reflecting the impact of 2025's challenges. The negative PEG ratio (-1.62) indicates current earnings are depressed, making valuation metrics less reliable.
UNH Technical Analysis
UnitedHealth's stock has demonstrated a robust recovery over the past year, with a 1-year price change of +29.99%, significantly outperforming the S&P 500's +18.56% over the same period. The current price of $392.95 sits at approximately 85% of the 52-week range (low: $255.97, high: $461.62), indicating the stock is trading closer to its highs but has pulled back from the peak. This positioning suggests a strong uptrend with recent consolidation, as the stock has retreated about 15% from its 52-week high of $461.62, yet remains well above its low, reflecting a healthy correction within a broader bullish trend.
Beta
0.63
0.63x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$256-$462
Price range past year
Annual Return
+27.9%
Cumulative gain past year
| Period | UNH Return | S&P 500 |
|---|---|---|
| 1m | -4.4% | +2.0% |
| 3m | +5.1% | +1.0% |
| 6m | +37.2% | +11.8% |
| 1y | +27.9% | +18.1% |
| ytd | +17.8% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNH Fundamental Analysis
UnitedHealth's revenue trajectory shows steady growth, with Q1 2026 revenue of $111.7 billion, up 1.96% year-over-year from $109.6 billion in Q1 2025. While the growth rate is modest, it marks a recovery from the stagnant revenue seen in late 2025, where Q4 2025 revenue was $113.2 billion, essentially flat. The company's revenue segments show UnitedHealthcare contributing $82.99 billion and OptumHealth $4.58 billion, indicating the insurance arm remains the primary driver, though Optum's growth is critical for margin expansion. The multi-quarter trend reveals a slight deceleration from Q1 2025's 2.0% growth, but the stability in revenue suggests a mature, resilient business model.
Quarterly Revenue
$111.7B
2026-03
Revenue YoY Growth
+2.0%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNH Overvalued?
Given UnitedHealth's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 24.95x, while the forward PE is 17.51x, implying the market expects significant earnings growth. This gap of 7.44x suggests investors are pricing in a strong recovery in profitability, supported by the estimated EPS of $34.29 for the next fiscal year, up from the trailing EPS of $15.75. The PEG ratio is negative at -1.62, indicating that earnings growth is expected to be high, but the negative value is due to the current earnings being depressed, making the metric less meaningful.
PE
25.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable, with a debt-to-equity ratio of 0.83 and interest expenses of $955 million in Q1 2026, which could strain earnings if rates rise. The company's net margin of 2.69% is thin, leaving little room for error, and the negative PEG ratio (-1.62) reflects depressed earnings that may not be sustainable. Revenue growth is modest at 1.96% YoY, indicating a mature business with limited organic expansion, and the reliance on government programs like Medicare exposes it to policy changes that could reduce reimbursement rates.